1. ALLA AKTIER
  2. NYHETER
  3. ACTIVE BIOTECH

Active Biotech

Nyheter Active Biotech Nyheter alla bolag

Active Biotech Interim Report Q2 2023

MAR

SECOND QUARTER IN BRIEF

  • Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (April 19)
  • Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (May 26)
  • Positive safety and tolerability in clinical phase I study and preclinical ocular biodistribution data supporting the further development of laquinimod eye drops for inflammatory eye diseases were established (May 30)
  • New preclinical data regarding tasquinimod's anti-fibrotic effects in myelofibrosis were presented at EHA 2023 (June 10)

EVENTS AFTER THE END OF THE PERIOD

  • Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
  • As communicated previously in the Q1, 2023 Interim Report, various sources of future financing are being explored, including partnering the company’s development programs, directed share issues to new investors, rights issue to current investors as well as other types of financing alternatives. These explorations remain ongoing. To secure the continued operations of Active Biotech, two major shareholders have provided a financing commitment to the Company of approximately 20 MSEK, to enable the time necessary to conclude on the ongoing opportunities being explored


FINANCIAL SUMMARY

SEK MApr-JunJan-JunFull-year

2023 20222023 20222022
Net sales
-
--
Operating profit/loss-11.3-14.0-23.1-29.3-57.9
Profit/loss after tax-11.2-14.3-22.7-30.0-58.4
Earnings per share (SEK)-0.04-0.07-0.09-0.14-0.25
Cash and cash equivalents (at close of period)

15.721.941.8

The report is also available at www.activebiotech.com

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: The wholly owned small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in clinical development for treatment of non-infectious uveitis and a clinical phase I study with a topical ophthalmic formulation has been concluded. Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

This information is information that Active Biotech is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-24 08:30 CEST.

Attachments

AB Rapport 2023 Q2 Eng

Datum 2023-08-24, kl 08:30
Källa MFN
Bifogade filer
AB Rapport 2023 Q2 Eng
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!